Intravenous tocilizumab improves clinical activity in moderate-to-severe thyroid eye disease patients.
Doctors spot four signs that predict which eye disease patients will heal fastest.
This retrospective cohort study evaluated intravenous tocilizumab in 234 patients with moderate-to-severe thyroid eye disease at Beijing Ton…
A new study reveals four simple blood tests that tell doctors if a specific eye drug will work for you soon.
Qualitative review of tocilizumab use with bispecific antibodies in relapsed/refractory multiple myeloma
New drugs for myeloma need a safety net to work well
This qualitative interview review synthesizes perspectives from ten hematologists/oncologists regarding bispecific antibody (BsAb) use in re…
New powerful drugs treat myeloma better, but patients need a safety net to handle side effects and stay on track for a long time.
Tisagenlecleucel in Korean patients with relapsed or refractory diffuse large B-cell lymphoma
New Lymphoma Therapy Helps Patients Live Longer
This retrospective cohort study of 79 Korean patients with relapsed or refractory diffuse large B-cell lymphoma evaluated tisagenlecleucel. …
A new study shows a specific immune therapy can shrink tumors and extend life for lymphoma patients who have run out of options.
Retrospective review of tocilizumab, rituximab, and azathioprine in chronic relapsing inflammatory optic neuropathy
New Clue Found in Stubborn Eye Inflammation
This retrospective analysis reviews tocilizumab, rituximab, and azathioprine use in 60 patients with chronic relapsing inflammatory optic ne…
Knowing a patient's blood marker status can guide doctors to the right therapy to stop recurring eye inflammation.
Hospitalized COVID-19 patients receiving antiviral, antiretroviral, or immunosuppressive treatments showed variable outcomes.
What helps hospitalized COVID-19 patients survive? A new model offers clues.
This cohort study of 711 hospitalized subjects with coronavirus evaluated antiviral, antiretroviral, and immunosuppressive treatments. Resul…
When COVID-19 hits hard, doctors need better tools to predict who might get worse. A study of 711 hospitalized patients found that factors l…
Biological DMARDs show marginal patient-reported outcome benefits over conventional therapy in early rheumatoid arthritis
Early rheumatoid arthritis patients report similar symptom relief with different treatment approaches
This open-label randomized trial in 795 newly diagnosed, DMARD-naïve RA patients compared three biological DMARDs plus methotrexate against …
In early rheumatoid arthritis, patients reported similar pain relief and quality-of-life improvements whether they started with conventional…